Advertisement
Advertisement
ANIP
ANI Pharmaceuticals, Inc.
78.25
USDSponsored
-4.38
-5.30%
Aug 07, 15:59 UTC -4
Closed
After-Market
77.42
-0.83
-1.07%
ANIP Earnings Reports
Positive Surprise Ratio
ANIP beat 29 of 43 last estimates.
67%
Next Report
Date of Next Report
Nov 05, 2026
Estimate for Q3 26 (Revenue/ EPS)
$302.67M
/$2.55
Implied change from Q2 26 (Revenue/ EPS)
+13.77%
/+15.38%
Implied change from Q3 25 (Revenue/ EPS)
+32.86%
/+25.00%
ANI Pharmaceuticals, Inc. earnings per share and revenue
On Aug 07, 2026, ANIP reported earnings of 2.21 USD per share (EPS) for Q2 26, beating the estimate of 2.09 USD, resulting in a 5.69% surprise. Revenue reached 266.04 million, compared to an expected 265.33 million, with a 0.27% difference. The market reacted with a -5.30% price change (close before vs. close after earnings).
Looking ahead to Q3 26, 7 analysts forecast an EPS of 2.55 USD, with revenue projected to reach 302.67 million USD, implying an increase of 15.38% EPS, and increase of 13.77% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Monte Rosa Therapeutics, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.39
Actual
-$0.43
Surprise
-9.58%
CytomX Therapeutics, Inc.
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.07
Actual
-$0.09
Surprise
-13.78%
Prime Medicine, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.26
Actual
-$0.24
Surprise
+8.57%
Prothena Corporation plc Ordinary Shares
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.39
Actual
-$0.32
Surprise
+19.76%
Ocugen, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.05
Actual
-$0.07
Surprise
-26.35%
X4 Pharmaceuticals, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.18
Actual
-$0.13
Surprise
+29.19%
Cellectis S.A. - ADR
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.27
Actual
-$0.22
Surprise
+20.89%
Entera Bio Ltd. Ordinary Shares
Report Date
Aug 07, 2026 For Q2 26
Estimate
-$0.08
Actual
-$0.14
Surprise
-71.57%
BioMarin Pharmaceuticals Inc
Report Date
Aug 06, 2026 For Q2 26
Estimate
$0.70
Actual
$1.20
Surprise
+71.04%
Aligos Therapeutics, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$1.09
Actual
-$0.14
Surprise
+87.21%
FAQ
What were ANI Pharmaceuticals, Inc.'s earnings and revenue for the latest quarter Q2 2026?
For Q2 2026, ANI Pharmaceuticals, Inc. reported EPS of $2.21, beating estimates by 5.69%, and revenue of $266.04M, 0.27% above expectations.
How did the market react to ANI Pharmaceuticals, Inc.'s Q2 2026 earnings?
The stock price moved down -5.3%, changed from $82.63 before the earnings release to $78.25 the day after.
When is ANI Pharmaceuticals, Inc. expected to report next?
The next earning report is scheduled for Nov 05, 2026.
What are the forecasts for ANI Pharmaceuticals, Inc.'s next earnings report?
Based on 7
analysts, ANI Pharmaceuticals, Inc. is expected to report EPS of $2.55 and revenue of $302.67M for Q3 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement